


What is claimed is:

1. A compound according to formula (I) hereinbelow:

or a pharmaceutically acceptable salt thereof.



5

R¹ is selected from the group consisting of H, CN, and halogen;

R² is selected from the group consisting of halogen and H;

R³ is selected from the group consisting of H and C₁₋₅ alkyl, optionally substituted;

10 n is 0 – 5;

R⁴ is selected from the group consisting of C₁₋₇ alkyl and cycloalkyl;

R⁵ is H or COR⁴; and

R⁶ is selected from the group consisting of aryl, fused aryl, dihydro, tetrahydro fused aryl, and heteroaryl, unsubstituted or substituted, with any substituent selected from the group
15 consisting of OH, halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, CF₃, OCF₃, CN and NO₂.

2. A compound according to claim 1 selected from the group consisting of:

3-[4-cyano-3-((2*R*)-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-2-[(3-methylbutanoyl)oxy]propyl)oxy]phenyl]propanoic acid hydrochloride;

20 3-[4-cyano-3-((2*R*)-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-2-[(2-methylpropanoyl)oxy]propyl)oxy]phenyl]propanoic acid hydrochloride;

3-[4-cyano-3-((2*R*)-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-2-[(2,2-dimethylpropanoyl)oxy]propyl)oxy]phenyl]propanoic acid hydrochloride;

3-[3-(((2*R*)-2-(acetyloxy)-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-

25 dimethylethyl]amino}propyl)oxy]-4-cyanophenyl]propanoic acid hydrochloride;

3-[4-cyano-3-(((2*R*)-2-[(cyclopropylcarbonyl)oxy]-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}propyl)oxy]phenyl]propanoic acid hydrochloride;

3-(4-cyano-3-{[(2*R*)-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-2-(D-valyloxy)propyl]oxy}phenyl)propanoic acid hydrochloride;

- 3-[3-((2*R*)-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-2-[(3-methylbutanoyl)oxy]propyl)oxy)-4,5-difluorophenyl]propanoic acid trifluoroacetate;
- 3-[3-((2*R*)-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-2-[(2-methylpropanoyl)oxy]propyl)oxy)-4,5-difluorophenyl]propanoic acid trifluoroacetate;
- 5 ethyl 3-{3-[(2*R*)-2-(acetyloxy)-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}propyl]oxy]-4-cyanophenyl}propanoate hydrochloride;
- ethyl 3-(3-{[(2*R*)-3-{acetyl[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-2-(acetyloxy)propyl]oxy}-4-cyanophenyl)propanoate;
- (1*R*)-2-({2-cyano-5-[3-(ethyloxy)-3-oxopropyl]phenyl}oxy)-1-({[2-(2,3-dihydro-1*H*-inden-
- 10 2-yl)-1,1-dimethylethyl]amino}methyl)ethyl 2-methylpropanoate hydrochloride;
- (1*R*)-2-({2-cyano-5-[3-(ethyloxy)-3-oxopropyl]phenyl}oxy)-1-({[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}methyl)ethyl 3-methylbutanoate hydrochloride;
- (1*R*)-2-({2-cyano-5-[3-(ethyloxy)-3-oxopropyl]phenyl}oxy)-1-({[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}methyl)ethyl 2,2-dimethylpropanoate hydrochloride;
- 15 (1*R*)-2-({2-cyano-5-[3-(ethyloxy)-3-oxopropyl]phenyl}oxy)-1-({[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}methyl)ethyl cyclopropanecarboxylate hydrochloride;
- ethyl 3-[4-cyano-3-({(2*R*)-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-2-[(trifluoroacetyl)oxy]propyl)oxy]phenyl]propanoate;
- 3-[3-((2*R*)-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-2-[(2,2-
- 20 dimethylpropanoyl)oxy]propyl)oxy)-4,5-difluorophenyl]propanoic acid;
- 3-[3-((2*R*)-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-2-[(phenylcarbonyl)oxy]propyl)oxy)-4,5-difluorophenyl]propanoic acid;
- 3-{3-[(2*R*)-2-(acetyloxy)-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}propyl]oxy}-4,5-difluorophenyl]propanoic acid;
- 25 (1*R*)-2-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-1-[(5-[3-(ethyloxy)-3-oxopropyl]-2,3-difluorophenyl)oxy)methyl]ethyl 3-methylbutanoate;
- (1*R*)-2-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-1-[(5-[3-(ethyloxy)-3-oxopropyl]-2,3-difluorophenyl)oxy)methyl]ethyl 2-methylpropanoate;
- (1*R*)-2-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-1-[(5-[3-(ethyloxy)-3-
- 30 oxopropyl]-2,3-difluorophenyl)oxy)methyl]ethyl 2,2-dimethylpropanoate;
- (1*R*)-2-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}-1-[(5-[3-(ethyloxy)-3-oxopropyl]-2,3-difluorophenyl)oxy)methyl]ethyl benzoate;

ethyl 3-{3-[[((2*R*)-2-(acetyloxy)-3-{[2-(2,3-dihydro-1*H*-inden-2-yl)-1,1-dimethylethyl]amino}propyl)oxy]-4,5-difluorophenyl}propanoate.

3. A method of antagonizing a calcium receptor, which comprises administering to a
5 subject in need thereof, an effective amount of a compound according to claim 1.

4. A method of treating a disease or disorder characterized by an abnormal bone or
mineral homeostasis, which comprises administering to a subject in need of treatment
thereof an effective amount of a compound of claim 1.
10

5. A method according to claim 4 wherein the bone or mineral disease or disorder is
selected from the group consisting of osteosarcoma, periodontal disease, fracture healing,
osteoarthritis, joint replacement, rheumatoid arthritis, Paget's disease, humoral
hypercalcemia, malignancy and osteoporosis.
15

6. A method according to claim 5 wherein the bone or mineral disease or disorder is
osteoporosis.

7. A method according to claim 6 wherein the compound is co-administered with an
20 anti-resorptive agent.

8. A method according to claim 7 wherein the anti-resorptive agent is selected from
the group consisting of estrogen, 1, 25 (OH)₂ vitamin D₃, calcitonin, selective estrogen
receptor modulators, vitronectin receptor antagonists, V-H⁺-ATPase inhibitors, src SH2
25 antagonists, bisphosphonates and cathepsin K inhibitors.

9. A method of increasing serum parathyroid levels which comprises administering to
a subject in need of treatment an effective amount of a compound of claim 1.

30 10. A method according to claim 9 wherein the compound is co-administered with an
anti-resorptive agent.

11. A method according to claim 10 wherein the anti-resorptive agent is selected from the group consisting of: estrogen, 1, 25 (OH)₂ vitamin D₃, calcitonin, selective estrogen receptor modulators, vitronectin receptor antagonists, V-H⁺-ATPase inhibitors, src SH2 antagonists, bisphosphonates and cathepsin K inhibitors.

5